Avlayah is the first Hunter syndrome therapy approved to address the condition’s neurologic complications, according to Tracy ...
FDA accelerated approval of tividenofusp alfa-eknm offers a new treatment for neurologic manifestations in patients with Hunter syndrome.
The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease, breaking the ...
The FDA approved a new medicine from Denali Therapeutics for Hunter syndrome, a notable decision by the agency after a string ...
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved ...
The FDA has given accelerated approval to Avlayah as a treatment for neurologic manifestations of Hunter syndrome, also known ...
A therapy for Hunter syndrome shows a significant reduction in disease-linked molecules in cerebrospinal fluid. Findings ...
The FDA granted accelerated approval to tividenofusp alfa (Avlayah) for the treatment of mucopolysaccharidosis type II (MPS ...
TransportVehicle-mediated transferrin receptor engagement enables CNS delivery of IDS, differentiating Avlayah from legacy ...
FDA approves first therapy for Hunter syndrome's neurologic symptoms via surrogate endpoint, signaling evolving rare disease ...
FDA OKs 1st Hunter syndrome therapy Avlayah to treat neurologic symptoms in pediatric patients with mucopolysaccharidosis Type 2.
The approval of Denali’s Hunter syndrome treatment, Avlayah, comes after a series of drug rejections and delays that had led ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results